Tanner CM - Search Results

1

Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.

Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, Shannon K, Wooten GF, Tanner CM, Goetz GC; NET-PD Investigators. Tilley BC, et al. Among authors: tanner cm. Neurology. 2006 Mar 14;66(5):628-33. doi: 10.1212/01.wnl.0000201251.33253.fb. Neurology. 2006. PMID: 16534099 Review.

2

Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.

Elm JJ; NINDS NET-PD Investigators. Elm JJ, et al. Mov Disord. 2012 Oct;27(12):1513-21. doi: 10.1002/mds.25175. Mov Disord. 2012. PMID: 23079770 Free PMC article. Clinical Trial.

3

Progression of Parkinson's disease without levodopa.

Goetz CG, Tanner CM, Shannon KM. Goetz CG, et al. Among authors: tanner cm. Neurology. 1987 Apr;37(4):695-8. doi: 10.1212/wnl.37.4.695. Neurology. 1987. PMID: 3561783

4

Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Dorsey ER, et al. Among authors: tanner cm. Neurology. 2007 Jan 30;68(5):384-6. doi: 10.1212/01.wnl.0000247740.47667.03. Epub 2006 Nov 2. Neurology. 2007. PMID: 17082464

5

Fatigue in levodopa-naive subjects with Parkinson disease.

Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S; Parkinson Study Group ELLDOPA Investigators. Schifitto G, et al. Neurology. 2008 Aug 12;71(7):481-5. doi: 10.1212/01.wnl.0000324862.29733.69. Neurology. 2008. PMID: 18695158 Free PMC article. Clinical Trial.

6

Agonist substitution in advanced Parkinson's disease.

Goetz CG, Shannon KM, Tanner CM, Carroll VS, Klawans HL. Goetz CG, et al. Among authors: tanner cm. Neurology. 1989 Aug;39(8):1121-2. doi: 10.1212/wnl.39.8.1121. Neurology. 1989. PMID: 2761708

7

Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.

Goetz CG, Tanner CM, Shannon KM, Carroll VS, Klawans HL, Carvey PM, Gilley D. Goetz CG, et al. Among authors: tanner cm. Neurology. 1988 Jul;38(7):1143-6. doi: 10.1212/wnl.38.7.1143. Neurology. 1988. PMID: 3290706 Clinical Trial.

8

Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).

Goetz CG, Tanner CM, Klawans HL, Shannon KM, Carroll VS. Goetz CG, et al. Among authors: tanner cm. Neurology. 1987 May;37(5):875-8. doi: 10.1212/wnl.37.5.875. Neurology. 1987. PMID: 3574696

9

Clonidine and Gilles de la Tourette's syndrome: double-blind study using objective rating methods.

Goetz CG, Tanner CM, Wilson RS, Carroll VS, Como PG, Shannon KM. Goetz CG, et al. Among authors: tanner cm. Ann Neurol. 1987 Mar;21(3):307-10. doi: 10.1002/ana.410210313. Ann Neurol. 1987. PMID: 3300518 Clinical Trial.

10

A rating scale for Gilles de la Tourette's syndrome: description, reliability, and validity data.

Goetz CG, Tanner CM, Wilson RS, Shannon KM. Goetz CG, et al. Among authors: tanner cm. Neurology. 1987 Sep;37(9):1542-4. doi: 10.1212/wnl.37.9.1542. Neurology. 1987. PMID: 3476860

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

347 results

Search Page

Filters